AbbVie Inc Congressional Trading
According to U.S. congressional financial disclosures filed under the STOCK Act, members of Congress have reported 313 trades in AbbVie Inc (NYSE: ABBV) since 2012, across 68 members, worth an estimated $5.5M in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts). 168 buys against 144 sells, a modestly buy-led skew, with Democratic members responsible for 48% of the trades and Republican members 52%. The most recent disclosure shown was filed July 2026, and Rohit Khanna has filed the most ABBV transactions among those shown, with 8. Other recent filers include Josh Gottheimer, Alan Armstrong, and Julie Johnson. One notable disclosed move was a purchase by Rohit Khanna on May 1, 2026, up 28.6% since. These figures are drawn from public House and Senate periodic transaction reports and reflect what members were required to disclose, not the current market value of any position. For the full record, including the month-by-month buy and sell timeline, the party breakdown, top buyers and sellers, and every individual filing, see the AbbVie Inc (ABBV) stock overview and the complete trade table below.
Data updated
Price & congressional trade timeline
Party breakdown
AbbVie congressional trading activity
| Politician | Published | Traded | Filed After | Type | Size | Return | Owner | |
|---|---|---|---|---|---|---|---|---|
 Rohit Khanna House | Jul 6, 2026 | Jun 2, 2026 | 34 days | BUY |  $1,001 - $15,000 | +23.39% | Child | |
Rohit Khanna House | Jun 9, 2026 | May 15, 2026 | 25 days | BUY | $15,001 - $50,000 | +26.33% | Spouse | |
 Josh Gottheimer House | Jun 3, 2026 | May 5, 2026 | 29 days | SELL | $1,001 - $15,000 | +28.96% | Joint | |
Rohit Khanna House | Jun 9, 2026 | May 1, 2026 | 39 days | BUY | $15,001 - $50,000 | +28.65% | Child | |
Rohit Khanna House | May 11, 2026 | Apr 13, 2026 | 28 days | SELL | $15,001 - $50,000 | +29.80% | Spouse | |
Rohit Khanna House | Apr 7, 2026 | Mar 30, 2026 | 8 days | SELL | $15,001 - $50,000 | +25.75% | Child | |
 Alan Armstrong Senate | Jul 21, 2026 | Mar 27, 2026 | 116 days | BUY | $15,001 - $50,000 | +27.98% | Self | |
Rohit Khanna House | Mar 9, 2026 | Feb 5, 2026 | 32 days | BUY | $15,001 - $50,000 | +22.36% | Spouse | |
Rohit Khanna House | Feb 6, 2026 | Jan 29, 2026 | 8 days | SELL | $15,001 - $50,000 | +21.58% | Spouse | |
Rohit Khanna House | Feb 6, 2026 | Jan 23, 2026 | 14 days | BUY | $1,001 - $15,000 | +22.23% | Child |
AbbVie (ABBV) congressional trading FAQ
Can members of Congress legally trade AbbVie (ABBV) stock?
Yes. Members of Congress are permitted to trade individual stocks, including AbbVie (ABBV), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; it does not imply any trade was improper.
Are congressional AbbVie (ABBV) trades public?
Yes. Every congressional trade in AbbVie (ABBV) on this page comes from mandatory public STOCK Act disclosure filings, which are filed with a delay and may be revised.
How many times has Congress traded AbbVie (ABBV)?
Members of Congress have disclosed 313 trades in AbbVie (ABBV) worth $5.5M across 68 members, according to public STOCK Act filings.
Which members of Congress have traded AbbVie (ABBV)?
Recent and active filers of AbbVie (ABBV) disclosures include Rohit Khanna, Lisa McClain, Julie Johnson. The full member-by-member trade list is on this page.
Do Democrats or Republicans trade AbbVie (ABBV) more?
Across disclosed AbbVie (ABBV) trades, 48% were by Democrats and 52% by Republicans, led by Republicans (52%).
What is the most recent congressional AbbVie (ABBV) trade?
The most recent disclosed AbbVie (ABBV) trade was a purchase by Alan Armstrong, filed Jul 20, 2026.
Browse all stocks Congress tradesCongressional trading overviewAbbVie (ABBV) stock overview
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. The Tide Score and other figures are generated algorithmically from public filings and market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.